Oura to acquire Counsel Health for $625 million as wearable company expands into primary care

Oura is acquiring AI-native primary care startup Counsel Health for $625 million, extending the smart-ring company’s strategy from tracking health metrics to helping users obtain medical advice and care. The transaction comes only weeks after Oura indefinitely postponed a planned IPO of up to $2.2 billion, citing uncertainty in public markets.

The deal formalizes a partnership that began in June, when Counsel’s service was integrated into the Oura app. Oura says the combined company will pursue preventative, acute, specialty and chronic care, while Counsel continues serving existing and new enterprise partners beyond Oura’s member base.

Oura’s move beyond wearable data

Counsel Health operates a chat-based medical service that combines medical AI with access to licensed physicians. Within the Oura app, users can ask health questions, receive personalized guidance and connect with a doctor when the system determines that human involvement is needed.

That gives Oura a broader role in the health journey. Its rings collect and present physiological information, while Counsel is intended to help turn that information into care-related action, including prescriptions, lab-result discussions, chronic-care support and referrals. Oura CEO Tom Hale described the combination in a company press release as a way to connect members’ understanding of their physiology with medical services.

The acquisition also addresses a strategic problem for Oura: wearable data can be valuable without necessarily becoming a recurring clinical relationship. By adding a care layer, Oura is attempting to make its platform more useful between routine health-tracking interactions and potentially more relevant to employers, health programs and other enterprise buyers.

Counsel’s clinical model and the role of AI

Counsel’s model is not presented as fully automated care. According to comments attributed to Counsel CEO Muthu Alagappan in the acquisition announcement, the company built its medical AI around trust, safety and physician involvement in clinical decisions.

Alagappan will join Oura as chief clinical AI officer, and Counsel’s roughly 70 employees are expected to move with the acquisition, Bloomberg reported through the TechCrunch coverage. The leadership appointment suggests that Oura views clinical governance as a central part of the transaction rather than treating Counsel as only a software or chatbot asset.

Oura’s data could provide clinicians with longitudinal context, including trended biometrics and indicators of member engagement. However, the available evidence does not establish how those signals will be used in clinical workflows, what information doctors can access, or how the companies will handle consent, privacy, escalation and medical liability. Those details will matter more than the conversational interface itself for healthcare buyers and regulators.

What the reported numbers show—and do not show

The $625 million purchase price is the clearest measure of Oura’s commitment to expanding into care. Counsel had raised $25 million in a Series A led by Andreessen Horowitz and GV about a year before the acquisition, while PitchBook estimated its total funding at $36 million. The difference between Counsel’s funding and its sale price reflects the value Oura places on its clinical platform, team and strategic fit, but does not by itself demonstrate revenue, clinical outcomes or broad adoption.

Oura also announced that revenue reached $533 million for the quarter ended September 30, up 153% year over year, and that fiscal 2026 revenue was approximately $1.75 billion, representing 92% annual growth. Those figures are company-reported and were included in the acquisition coverage; the available source material does not provide independent verification or a breakdown showing how much came from subscriptions, hardware, enterprise contracts or health services.

The company reached an $11 billion valuation after a $900 million late-stage funding round in October 2025. Its subsequent decision to postpone the IPO indefinitely adds financial-market context to the acquisition. Oura may be using a private-market balance sheet to invest in a new growth category while public-market conditions remain uncertain, but the deal should not be read as evidence that the acquisition will immediately improve profitability or prepare the company for a near-term listing.

Implications for builders and healthcare buyers

For AI product teams, the transaction highlights the limits of treating medical AI as a standalone chat experience. Counsel’s value to Oura appears to come from combining software with licensed clinicians, existing user engagement and a stream of wearable information. Building that system requires more than model performance: teams must design escalation paths, record clinical decisions, preserve human accountability and determine when an answer is not safe to automate.

For enterprise buyers, Counsel’s continued work with partners is an important condition of the deal. Oura says the company will keep serving existing and new enterprise customers while extending its AI-native care model beyond Oura members. That could allow the acquired business to develop as a broader healthcare product rather than becoming an exclusive feature for ring users.

The competitive pressure is also specific. Oura has dominated the smart-ring market for years, but RingConn and Ultrahuman are emerging rivals. A move into primary care could differentiate Oura through services rather than sensor hardware, although it also brings additional regulatory, operational and reputational risk. Medical guidance creates a higher bar for reliability than wellness recommendations, and errors could affect trust in both Counsel and the Oura brand.

What to watch next

The first signal will be how Oura defines the boundaries between wellness insights and clinical care inside the Oura app. Details on physician access, prescription workflows, referrals, lab-result handling and chronic-care programs will show whether the combined product is a practical care service or primarily a conversational layer around existing providers.

Enterprise expansion will be another test. Oura has said Counsel will continue serving partners, but it has not disclosed contract counts, customer growth, healthcare outcomes or the economics of those relationships. Buyers will likely look for evidence on implementation costs, response times, clinician workloads, patient safety and whether wearable data produces better decisions rather than simply more data.

Finally, investors will watch whether the acquisition changes Oura’s IPO plans. The company’s revenue growth and $11 billion valuation create a substantial expectation for expansion, while the postponed listing indicates that market timing remains unsettled. The next financial disclosures may clarify how much capital Oura is directing toward clinical operations and whether care becomes a meaningful business line.

Creati.ai perspective

Oura’s purchase of Counsel Health is notable because it joins a consumer health interface with a physician-backed AI service, rather than adding another general-purpose assistant to a wearable. The strategic logic is clear: physiological data becomes more valuable when it can inform a next step. But the difficult work will be clinical integration, governance and accountability, not the chatbot layer.

The acquisition will matter to AI builders if Oura can show that medical AI improves access and care coordination without weakening safety controls. Until the companies disclose more about outcomes, enterprise adoption and operating economics, the $625 million price is best viewed as a strong bet on the combination of longitudinal health data and human-supervised care—not proof that the model has already scaled.